X O Breakefield

Rapid‐onset dystonia‐parkinsonism

X. Breakefield, M. Farlow, W. Dobyns, 1993, Neurology.

Prodrug activation enzymes in cancer gene therapy

X. Breakefield, F. Hochberg, M. Aghi, 2000, The journal of gene medicine.

Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.

X. Breakefield, T. Chou, C. Kramm, 1998, Journal of the National Cancer Institute.

Adult onset idiopathic torsion dystonia is excluded from the DYT 1 region (9q34) in a Swedish family.

L Forsgren, S Fahn, X. Breakefield, 1995, Journal of neurology, neurosurgery, and psychiatry.

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

X. Breakefield, L. Mincheva-Nilsson, J. Skog, 2009, British Journal of Cancer.

Biochemistry and genetics of monoamine oxidase.

X. Breakefield, W. Weyler, X O Breakefield, 1990, Pharmacology & therapeutics.

Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.

S Fahn, M. Brin, X. Breakefield, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.

X. Breakefield, T. Chou, E. Chiocca, 1999, Cancer research.

Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation

S Fahn, M. Brin, X. Breakefield, 1994, Annals of neurology.